Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor‐induced colitis

医学 英夫利昔单抗 内科学 四分位间距 泼尼松龙 胃肠病学 溃疡性结肠炎 回顾性队列研究 不利影响 结肠炎 外科 肿瘤坏死因子α 疾病
作者
Erik Dahl,Osama Karim Abed,Jens Kjeldsen,Marco Donia,Inge Marie Svane,Anders Dige,Jørgen Agnholt,Jacob Tveiten Bjerrum,Jakob Benedict Seidelin
出处
期刊:Alimentary Pharmacology & Therapeutics [Wiley]
卷期号:56 (9): 1370-1382 被引量:10
标识
DOI:10.1111/apt.17201
摘要

Cancer patients treated with immune check point inhibitors are at risk of developing severe colitis. However, the efficacy and safety of treatment of severe colitis is poorly understood.To explore the safety and efficacy of infliximab and corticosteroids in severe immune-mediated enterocolitis (IMC) METHOD: We performed a nationwide retrospective cohort study on 140 cancer patients treated with infliximab due to IMC in Denmark from 2011 to 2021.The rate of complete remission with infliximab was 52% after one dose, increasing to 73% after two or more doses. Thirteen patients (10%) required additional treatment with vedolizumab. Patients were heavily exposed to corticosteroids and received a median accumulated dose of 3978 mg (interquartile range [IQR] 2552-6414). Age- and cancer-adjusted Cox regression analysis found that a high dose of prednisolone at start of tapering ≥75 mg/day was associated with increased mortality (HR 1.67, 1.04-2.69, p = 0.035). Patients responding to infliximab experienced an improvement of symptoms after 3 days (IQR 2-4) and complete remission after 31 days (IQR 14-61). Twenty-four percent required hospitalisation for infection during treatment for IMC, lasting 7 days (median). Secondary gastrointestinal infections occurred in 16%, with Clostridioides difficile being most common (64%). Further, 10% had a thromboembolic event during the first 90 days after infliximab treatment.Infliximab led to complete resolution of symptoms in 73% of patients with IMC. High prednisolone dose at tapering was associated with increased mortality rate and a high incidence of infections and hospitalisations in patients with severe IMC. We suggest optimised infliximab treatment before escalation of steroid doses.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
明天过后完成签到,获得积分10
2秒前
jin完成签到,获得积分10
3秒前
yhy完成签到 ,获得积分10
4秒前
黑色卡布奇诺完成签到,获得积分20
4秒前
tanglu发布了新的文献求助10
4秒前
可爱的函函应助梁大海采纳,获得10
4秒前
成就绮琴完成签到 ,获得积分10
5秒前
xicifish完成签到,获得积分10
5秒前
目光之澄完成签到,获得积分10
6秒前
wanci应助研友_ndDPBn采纳,获得10
6秒前
耍酷的白梦完成签到,获得积分10
7秒前
miracle完成签到 ,获得积分10
8秒前
coding完成签到,获得积分10
9秒前
10秒前
犹豫水蓝完成签到,获得积分10
11秒前
yin完成签到,获得积分10
11秒前
JUGG完成签到,获得积分10
11秒前
CipherSage应助阿湫采纳,获得10
12秒前
FIN应助手机采纳,获得20
12秒前
星辰大海应助东黎采纳,获得10
12秒前
量子星尘发布了新的文献求助10
12秒前
wujingshuai完成签到,获得积分10
13秒前
少年完成签到,获得积分10
13秒前
星辰大海应助ficus_min采纳,获得10
14秒前
小柒柒完成签到,获得积分10
15秒前
sdfwsdfsd完成签到,获得积分10
16秒前
亮仔完成签到,获得积分10
17秒前
土豆丝发布了新的文献求助10
17秒前
ylw完成签到,获得积分20
18秒前
西门明雪完成签到,获得积分10
18秒前
18秒前
烟花应助万松辉采纳,获得10
19秒前
爆米花应助不站在雾里采纳,获得10
19秒前
yy完成签到,获得积分20
20秒前
高贵宛海完成签到,获得积分10
20秒前
854fycchjh完成签到,获得积分10
21秒前
22秒前
研友_ndDPBn发布了新的文献求助10
22秒前
番茄发布了新的文献求助30
22秒前
上官若男应助fw20210085采纳,获得10
23秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038524
求助须知:如何正确求助?哪些是违规求助? 3576221
关于积分的说明 11374737
捐赠科研通 3305912
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892688
科研通“疑难数据库(出版商)”最低求助积分说明 815048